Table 1 Baseline characteristics of include trials
Author | Single vs. Multicenter | Regions | Average age(Years) (I/C) | Gestational age(Weeks)(I/C) | Duration of rupture of membranes (Hours) (I/C) | Sample size(n) | |
|---|---|---|---|---|---|---|---|
Azithromycin group (M/N) | Placebo group (M/N) | ||||||
Tita 2016 | Multicenter | America | 28.2 ± 6.1/ 28.4 ± 6.5 | 38.9 ± 2.3/ 39.0 ± 2.3 | NA | 1,019/ 1,019 | 994/994 |
Oluwalan-a 2017 | Single | Gambia | IQR: 26(22–30)/ 25(22–30) | IQR: 36(35–38)/ 36(35–38) | 0.4(0.1–1.8)/ 0.3(0.1–1.3) | 414/419 | 415/424 |
Jyothi 2019 | Single | Chandigarh and India | 26.42 ± 2.65/ 27.39 ± 3.03 | 36.41 ± 2.77/36.75 ± 2.71 | 4.48 ± 3.87/ 4.34 ± 4.01 | 100/100 | 100/100 |
Subrama-niam 2021 | Multicenter | Cameroon | 27.2 ± 5.3/ 26.0 ± 5.3 | 39.4 ± 1.5/ 39.2 ± 1.4 | 15.7(2.6–29.7)/15.6 (3.4–27.7) | 253/257 | 250/255 |
Roca 2023 | Multicenter | Gambia and Burkina Faso | IQR: 27(22–31)/ 26 (22–31) | NA | 0.3(0.1–1.5)/ 0.3 (0.1–1.4) | 5,802/ 5,889 | 5,823/ 5,894 |
Tita 2023 | Multicenter | Africa,Asia and Latin America | IQR: 24(21–28)/ 24 (21–28) | 38.9 ± 2.3/ 39.0 ± 2.3 | NA | 14,590/ 14,687 | 14,688/ 14,782 |